Expression of X-linked Inhibitor of Apoptosis Protein in Neoplastic Thyroid Disorder
Ji-Hye YIM; Jong-Ho YOON; Sun-A KIM; Won-Gu KIM; Min-Ji JEON; Ji-Min HAN; Tae-Yon SUNG; Tae-Yong KIM; Won-Bae KIM; Suck-Joon HONG; Young-Kee SHONG; Gyungyub GONG.
Journal of Korean Medical Science
; : 1191-1195, 2011.
Artículo
en Inglés
| WPRIM | ID: wpr-28040
X-linked inhibitor of apoptosis protein (XIAP) is associated with tumor genesis, growth, progression and metastasis, and acts by blocking caspase-mediated apoptosis. In the present study, we sought to evaluate the expression patterns of XIAP in various neoplastic thyroid disorders and determine the association between XIAP expression and clinicopathologic factors. Expression of XIAP was evaluated with immunohistochemical staining using monoclonal anti-XIAP in 164 specimens of conventional papillary thyroid carcinoma (PTC) and 53 specimens of other malignant or benign thyroid tumors. XIAP positivity was observed in 128 (78%) of the 164 conventional PTC specimens. Positive rates of XIAP expression in follicular variant PTC, follicular, medullary, poorly differentiated, and anaplastic thyroid carcinoma specimens were 20%, 25%, 38%, 67%, and 38%, respectively. Six nodular hyperplasia specimens were negative and 1 of 7 follicular adenomas (8%) was positive for XIAP. Lateral neck lymph node metastases were more frequent in patients negative for XIAP expression (P = 0.01). Immunohistochemical staining for XIAP as a novel molecular marker may thus be helpful in the differential diagnosis of thyroid cancer. Moreover, high XIAP expression in conventional PTC is strongly associated with reduced risk of lateral neck lymph node metastasis.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados